This Article Full Text Full Text (PDF) Methods Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Münzel, T. Articles by Förstermann, U. Search for Related Content PubMed PubMed Citation Articles by Münzel, T. Articles by Förstermann, U. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-ARGININE NITRIC OXIDE NITROGLYCERIN Related Collections Gene expression Endothelium/vascular type/nitric oxide

(Circulation Research. 2000;86:e7.)
© 2000 American Heart Association, Inc.

UltraRapid Communications

Effects of Long-Term Nitroglycerin Treatment on Endothelial Nitric Oxide Synthase (NOS III) Gene Expression, NOS III–Mediated Superoxide Production, and Vascular NO Bioavailability

Thomas Münzel, Huige Li, Hanke Mollnau, Ulrich Hink, Edi Matheis, Mark Hartmann, Mathias Oelze, Mikhail Skatchkov, Ascan Warnholtz, Linda Duncker, Thomas Meinertz, Ulrich Förstermann

From the University Hospital Eppendorf (T.M., H.M., U.H., E.M., M.H., M.O., M.S., A.W., L.D., T.M.), Division of Cardiology, Hamburg, and the Department of Pharmacology (H.L., U.F.), Johannes Gutenberg University, Mainz, Germany.

Correspondence to Thomas Münzel, MD, Universitätskrankenhaus Eppendorf, Abteilung für Kardiologie, Martinistrasse 52, 20246 Hamburg, Germany. E-mail muenzel{at}uke.uni-hamburg.de

Abstract—Long-term nitroglycerin (NTG) treatment has been shown to be associated with cross-tolerance to endothelium-dependent vasodilators. It may involve increased production of reactive oxygen species (such as superoxide, O₂^·-) that rapidly inactivate the nitric oxide (NO) released from the endothelial cells. It remains to be elucidated, however, whether long-term treatment with NTG alters the activity and expression of the endothelial NO synthase (NOS III) and whether this enzyme can contribute to O₂^·- formation. We studied the influence of long-term NTG treatment on the expression of NOS III as assessed by RNase protection assay and Western blot. Tolerance was measured ex vivo in organ chamber experiments with rat aortic rings. O₂^·- and NO formation were quantified using lucigenin- and Cypridina luciferin analog–enhanced chemiluminescence as well as electron spin resonance (ESR) spectroscopy. Treatment of Wistar rats with NTG (Alzet osmotic minipumps, NTG concentration 10 µg · kg^-1 · min^-1) for 3 days caused marked tolerance, cross-tolerance to the endothelium-dependent vasodilator acetylcholine, and a significant increase in O₂^·--induced chemiluminescence. Tolerance was associated with a significant increase in NOS III mRNA to 236±28% and NOS III protein to 239±17%. In control vessels, the NOS inhibitor N^G-nitro-L-arginine (L-NNA) increased the O₂^·--mediated chemiluminescence, indicating that basal production of endothelium-derived NO depresses the baseline chemiluminescence signal. In the setting of tolerance, however, L-NNA decreased steady-state O₂^·- levels, indicating the involvement of NOS III in O₂^·- formation. Likewise, A23187-induced, NOS III–mediated O₂^·- production was more pronounced in tolerant than in control vessels. Vascular NO bioavailability as assessed with ESR spectroscopy using iron-thiocarbamate as a trap for NO was significantly reduced in tolerant vessels. Pretreatment of tolerant tissue in vitro with the protein kinase C (PKC) inhibitors reduced basal and stimulated NOS III–mediated O₂^·- production and partially reversed vascular tolerance. These findings suggest that NTG treatment increases the expression of a dysfunctional NOS III gene, leading to increased formation of O₂^·- and decreased vascular NO bioavailability. Normalization of NOS III–mediated O₂^·- production and improvement of tolerance with PKC inhibition suggests an important role for PKC isoforms in mediating vascular dysfunction caused by long-term NTG treatment. The full text of this article is available at http://www.circresaha.org.

Key Words: nitrate tolerance • nitric oxide synthase uncoupling • electron spin resonance

This article has been cited by other articles:

				R. Parent, N. Leblanc, and M. Lavallee Nitroglycerin reduces myocardial oxygen consumption during exercise despite vascular tolerance Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1226 - H1234. [Abstract] [Full Text] [PDF]

				D. W. Stepp, J. Ou, A. W. Ackerman, S. Welak, D. Klick, and K. A. Pritchard Jr. Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascular endothelium in situ Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H750 - H759. [Abstract] [Full Text] [PDF]

				Y. Zhang, J. W. Bissing, L. Xu, A. J. Ryan, S. M. Martin, F. J. Miller Jr, K. C. Kregel, G. R. Buettner, and R. E. Kerber Nitric oxide synthase inhibitors decrease coronary sinus-free radical concentration and ameliorate myocardial stunning in an ischemia-reperfusion model J. Am. Coll. Cardiol., August 1, 2001; 38(2): 546 - 554. [Abstract] [Full Text] [PDF]

				J. D. Ratz, A. B. Fraser, K. J. Rees-Milton, M. A. Adams, and B. M. Bennett Endothelin Receptor Antagonism Does Not Prevent the Development of In Vivo Glyceryl Trinitrate Tolerance in the Rat J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 578 - 585. [Abstract] [Full Text]

				T. J. Guzik, S. Mussa, D. Gastaldi, J. Sadowski, C. Ratnatunga, R. Pillai, and K. M. Channon Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase Circulation, April 9, 2002; 105(14): 1656 - 1662. [Abstract] [Full Text] [PDF]